MediPharm Labs Corp (CVE:LABS) Reports Adjusted EBITDA of $2.1 Million 2

MediPharm Labs Corp (CVE:LABS) Reports Adjusted EBITDA of $2.1 Million

MediPharm Labs Corp (CVE:LABS) (OTCMKTS:MEDIF) (FRA:MLZ) President Keith Strachan has nothing but praise for the MediPharm team in light of the company’s recent financial reporting. MediPharm recently released its Q4 financials for the period ending December 31, 2018 and the results were impressive. The company reported revenue of $10.2 million and adjusted EBITDA of $2.1 million. The pure play extractor has partnerships with Canopy Growth Corp (TSE:WEED) (NYSE:CGC) (FRA:11L1) and Supreme Cannabis Company Inc (TSE:FIRE) (OTCMKTS:SPRWF) (FRA:53S1). MediPharm Labs is strictly a B2B company and Strachan explains that its private label approach provides a turnkey model for established brands to enter the cannabis space. While price competition in the extraction space is a concern, Strachan believes the company’s turnkey offerings, in addition to MediPharm’s specialized end products and secure supply chain, will offset any commodity pricing in the space.


Check out our website:



SUBSCRIBE to our YouTube:

SUBSCRIBE to our 2nd YouTube Channel – Midas Letter Clips:

SUBSCRIBE to our Newsletter:

Download Our Podcast on iTunes:


Follow Us on Twitter:

Like Us on Instagram:

Like Us on Facebook:




Leave a Comment

Your email address will not be published. Required fields are marked *

error: Content is protected !!


Click one of our representatives below to chat on WhatsApp or send us an email to [email protected]


× Order Via Whatsapp?